Dr. Yasser A. Khaled, MD

Dr. Khaled practices at Arnold Palmer Hospital for Children in Orlando, Florida.

Dr. Khaled's NPI, 1023194982, was assigned on October 31, 2006. Dr. Khaled graduated from Other in 1990. Dr. Khaled holds Florida license ME104304.

Dr. Khaled's primary practice is Arnold Palmer Hospital for Children, at 92 W Miller St, Orlando, FL 32806 in Orange County. The practice phone is (407) 650-5028.

Dr. Khaled's primary practice is Arnold Palmer Hospital for Children in Orlando, Florida. Dr. Khaled is also affiliated with Orlando Regional Medical Center. The medical group on file is Orlando Health Medical Group. Dmand AI also links Dr. Khaled to 3 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Khaled practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Khaled's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Khaled is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Khaled's licenses on file in 6 states: Florida, Tennessee, Michigan, Texas, Virginia and Georgia.

Dmand AI lists chronic leukemia, lymphoma and multiple myeloma among the conditions Dr. Khaled treats.

CMS data shows 481 Medicare services from Dr. Khaled across 5 procedure codes in 2024, for 44 Medicare patients. Medicare paid $32,488 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 44 Medicare patients who saw Dr. Khaled in 2024. The largest group is 65 to 74, with 31 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 3.22, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Khaled's median patient age at 69, with 46% women.

In 2024, Dr. Khaled wrote 183 Medicare Part D claims for 32 patients. CMS names the drug for 98 of them, across 5 drugs with 11 or more claims each, at $903,752 in total drug cost. In 2023, CMS named 113 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 80 out of 100 for Dr. Khaled for performance year 2024, reported as part of a group. Dr. Khaled accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 22 papers to Dr. Khaled, published from 2007 to 2025. 2009 was the busiest year, with 6. The most frequent topics are Graft vs Host Disease, Hematopoietic Stem Cell Transplantation and Transplantation Conditioning. Dr. Khaled has published most often in Bone Marrow Transplant. Dr. Khaled's most frequent co-authors are Oleg I. Krijanovski, MD, PhD, Edward M. Peres, MD and Gregory A. Yanik, MD.

Dmand AI links Dr. Khaled to 3 clinical trials, 2 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Multiple Myeloma, Anemia, Aplastic and Disease Progression.

CMS Open Payments shows 508 general payments to Dr. Khaled from 26 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 80% of the total. Jazz Pharmaceuticals Inc. paid the most, $115,288.

Dr. Khaled graduated from Other in 1990.

Dr. Khaled is in network with 16 carriers, including Elevance, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.